Abstract Number: 1749 • 2019 ACR/ARP Annual Meeting
Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used in the treatment of autoimmune diseases. However, its use is associated with progressive irreversible retinal damage and vision loss…Abstract Number: 2105 • 2019 ACR/ARP Annual Meeting
The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids
Background/Purpose: Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as a first-line agent of pneumocystis pneumonia (PCP) prophylaxis for those who receive prolonged high-dose glucocorticoids. Alternative agents can be…Abstract Number: 2268 • 2019 ACR/ARP Annual Meeting
Preferences and Insights for Rheumatoid Arthritis Clinical Prevention Trial Participation
Background/Purpose: In rheumatoid arthritis (RA) development, autoantibodies to citrullinated protein antigens (ACPA) are elevated in the blood before clinically-apparent synovitis develops. These findings underpin the…Abstract Number: 295 • 2018 ACR/ARHP Annual Meeting
Implementing a Staff Tobacco Cessation Protocol Increases Quit Line Referrals in a Community Rheumatology Practice
Background/Purpose: Smoking remains the leading preventable cause of US mortality and predicts higher incidence, greater severity, and reduced treatment response in many rheumatologic conditions. Despite…Abstract Number: 344 • 2018 ACR/ARHP Annual Meeting
Use of Lean Six-Sigma Methodologies to Improve Pneumococcal Vaccination Rates Among Immunocompromised Veterans with Rheumatologic Diseases: A Quality Improvement Project
Background/Purpose: Pneumonia is a leading cause of morbidity and mortality in the United States among immunocompromised individuals with rheumatologic diseases. Despite the publication of Advisory…Abstract Number: 1235 • 2018 ACR/ARHP Annual Meeting
Isoniazid Monotherapy As a Prophylaxis for Tuberculosis in Patients with Rheumatic Diseases Exposed to Prolonged, High-Dose Glucocorticoids
Background/Purpose: Although use of glucocorticoid increases the risk of tuberculosis (TB) disease, there has been few studies investigating its incidence and risk/benefit assessment of the…Abstract Number: 1596 • 2018 ACR/ARHP Annual Meeting
Atherosclerotic Cardiovascular Disease in Psoriatic Arthritis: Evaluation of Risk Factor Management and Use of Aspirin and Statin for Prevention in a Primary Care Setting
Background/Purpose: There is accumulating evidence that shows an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) risk factors among the psoriatic arthritis (PsA) population. The aim…Abstract Number: 1642 • 2018 ACR/ARHP Annual Meeting
Systematic Screening of Comorbidities Improves Vaccination Rates, Skin Cancer Screening and Vitamin D Supplementation in Patients with Axial Spondyloarthritis: Results of a Prospective, Controlled ,One Year Randomised Trial
Background/Purpose: Specific recommendations for the detection/prevention of comorbidities have been proposed for patients with SpA. However, we know that often a gap exists between recommendation…Abstract Number: 1909 • 2018 ACR/ARHP Annual Meeting
Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women
Background/Purpose: Compared to never smoking, past and current smoking are both associated with increased risk of seropositive rheumatoid arthritis (RA). Thus, smoking cessation may delay…Abstract Number: 841 • 2017 ACR/ARHP Annual Meeting
Optimal Regimens of Sulfamethoxazole-Trimethoprim for Chemoprophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Diseases: 52-Week Follow-up of a Non-Blinded, Randomized Controlled Trial
Background/Purpose: Sulfamethoxazole-trimethoprim (SMX/TMP) is a standard drug for the prophylaxis of Pneumocystis pneumonia (PCP), but is sometimes discontinued due to adverse events (AEs). We have…Abstract Number: 2026 • 2017 ACR/ARHP Annual Meeting
Pneumococcal Vaccination Rates: Improving Safety in Immunocompromised Patients
Background/Purpose: Streptococcus pneumoniae is the most common cause of bacterial pneumonia.1 Invasive pneumococcal infections carry a 10% mortality rate, which is higher in the immunosuppressed.1…Abstract Number: 2250 • 2017 ACR/ARHP Annual Meeting
Linguistic Differences in Gout-Related Online Content: A Comparison of Professional Health Literature for Consumers Vs Patients’ Online Discussions of Gout
Background/Purpose: Non-adherence to gout medication is high. This may be due in part to patients’ belief that gout is primarily caused by overindulgence in certain…Abstract Number: 2760 • 2017 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository (“Registry”) Analysis: First and Recurrent Thrombosis Risk after 1201 Patient-Years of Follow-up
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…Abstract Number: 422 • 2016 ACR/ARHP Annual Meeting
Developing a Staff-Driven Electronic Smoking Cessation Referral Program in Rheumatology Clinics
Background/Purpose: Patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) have an increased risk of premature cardiovascular disease (CVD), making comorbid risk factors like…Abstract Number: 425 • 2016 ACR/ARHP Annual Meeting
Improving Pneumococcal Vaccination Rates for Immunosuppressed Patients in an Academic Rheumatology Clinic
Background/Purpose: Patients with autoimmune conditions have higher rates of pneumococcal disease and they are often immunosuppressed. In 2014, the Advisory Committee on Immunization Practices issued…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- Next Page »